Embolotherapy Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2030)
Get a Comprehensive Overview of the Embolotherapy Market Report Prepared by P&S Intelligence, Segmented by Product (Embolic Agents, Support Devices), Procedure (Transcatheter Arterial Embolization, Transarterial Radioembolization/Selective Internal Radiation Therapy, Transarterial Chemoembolization), Indication (Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological and nephrological disorders, Gastrointestinal Disorders) End User (Hospitals and Clinics, Ambulatory Surgical Centers), and Geographic Regions. This Report Provides Insights From 2017 to 2024
Chapter 1. Research Background
1.1 Research Objectives
1.2 Market Definition
1.3 Analysis Period
1.4 Market Data Reporting Unit
1.4.1 Value
1.5 Market Size Breakdown by Segment
1.5.1 Market Segmentation by Product
1.5.2 Market Segmentation by Procedure
1.5.3 Market Segmentation by Indication
1.5.4 Market Segmentation by End User
1.5.5 Market Segmentation by Region
1.6 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.1.1 Paid
2.1.2 Unpaid
2.1.3 P&S Intelligence Database
2.2 Primary Research
2.2.1 Breakdown of Primary Research, by Region
2.2.2 Breakdown of Primary Research, by Industry Participant
2.2.3 Breakdown of Primary Research, by Company Type
2.3 Market Size Estimation
2.4 Data Triangulation
2.5 Currency Conversion Rates
Chapter 3. Executive Summary
Chapter 4. Introduction
4.1 Definition of Market Segments
4.1.1 By Product
4.1.1.1 Embolic agents
4.1.1.1.1 Microspheres
4.1.1.1.2 Bland PVA particles
4.1.1.1.3 Embolic coils
4.1.1.1.4 Liquid embolic agents
4.1.1.1.5 Embolic plug systems
4.1.1.1.6 Detachable balloons
4.1.1.2 Support devices
4.1.1.2.1 Microcatheters
4.1.1.2.2 Guidewires
4.1.2 By Procedure
4.1.2.1 TAE
4.1.2.2 TARE/SIRT
4.1.2.3 TACE
4.1.3 By Indication
4.1.3.1 Cancer
4.1.3.1.1 Kidney
4.1.3.1.2 Liver
4.1.3.1.3 Others
4.1.3.2 Peripheral vascular diseases
4.1.3.3 Neurological diseases
4.1.3.3.1 Cerebral aneurysms
4.1.3.3.2 Arteriovenous malformations and fistulas
4.1.3.4 Urological and nephrological disorders
4.1.3.5 Gastrointestinal disorders
4.1.4 By End User
4.1.4.1 Hospitals and clinics
4.1.4.2 ASCs
4.1.4.3 Others
4.2 Market Dynamics
4.2.1 Trends
4.2.1.1 Increasing number of product approvals and launches
4.2.1.2 Increasing number of acquisitions
4.2.1.3 Technological advancements in embolotherapy devices
4.2.2 Drivers
4.2.2.1 Increasing prevalence of chronic and lifestyle-associated diseases
4.2.2.2 Growing medical tourism sector
4.2.2.3 Rising healthcare expenditure and improving healthcare infrastructure
4.2.2.4 Surging patient preference for MISs
4.2.2.5 Impact analysis of drivers on market forecast
4.2.3 Restraints
4.2.3.1 Risks and challenges associated with embolization
4.2.3.2 Strong market positioning of alternative therapies
4.2.3.3 Dearth of skilled radiologists
4.2.3.4 Impact analysis of restraints on market forecast
4.2.4 Opportunities
4.2.4.1 Growing applications of liquid embolic agents
4.2.4.2 Untapped market in developing economies
4.2.4.3 Increasing adoption of image-guided procedures
4.3 Porter’s Five Forces Analysis
Chapter 5. Global Market Size and Forecast
5.1 Global Market Size and Forecast
5.2 By Product
5.2.1 Embolic Agents Market, by Type
5.2.2 Embolotherapy Support Devices Market, by Type
5.3 By Procedure
5.3.1 TAE Market, By Product
5.3.1.1 TAE Embolic Agents Market, by Type
5.3.1.2 TAE Support Devices Market, by Type
5.3.2 TACE Market, By Product
5.3.2.1 TACE Embolic Agents Market, by Type
5.3.2.2 TACE Support Devices Market, by Type
5.3.3 TARE Market, By Product
5.3.3.1 TARE Embolic Agents Market, by Type
5.3.3.2 TARE Support Devices Market, by Type
5.4 By Indication
5.4.1 Embolotherapy Market for Cancer, by Type
5.4.1.1 Liver Cancer Embolotherapy Market, By Product
5.4.1.1.1 Liver Cancer Embolic Agents Market, by Type
5.4.1.2 Kidney Cancer Embolotherapy Market, By Product
5.4.1.2.1 Kidney Cancer Embolic Agents Market, by Type
5.4.1.3 Other Cancer Embolotherapy Market, By Product
5.4.1.3.1 Other Cancer Embolic Agents Market, by Type
5.4.2 Embolotherapy Market for Neurological Diseases, by Type
5.5 By End User
5.6 By Region
Chapter 6. North America Market Size and Forecast
6.1 By Product
6.1.1 Embolic Agents Market, by Type
6.1.2 Embolotherapy Support Devices Market, by Type
6.2 By Procedure
6.2.1 TAE Market, By Product
6.2.1.1 TAE Embolic Agents Market, by Type
6.2.1.2 TAE Support Devices Market, by Type
6.2.2 TACE Market, By Product
6.2.2.1 TACE Embolic Agents Market, by Type
6.2.2.2 TACE Support Devices Market, by Type
6.2.3 TARE Market, By Product
6.2.3.1 TARE Embolic Agents Market, by Type
6.2.3.2 TARE Support Devices Market, by Type
6.3 By Indication
6.3.1 Embolotherapy Market for Cancer, by Type
6.3.1.1 Liver Cancer Embolotherapy Market, By Product
6.3.1.1.1 Liver Cancer Embolic Agents Market, by Type
6.3.1.2 Kidney Cancer Embolotherapy Market, By Product
6.3.1.2.1 Kidney Cancer Embolic Agents Market, by Type
6.3.1.3 Other Cancer Embolotherapy Market, By Product
6.3.1.3.1 Other Cancer Embolic Agents Market, by Type
6.3.2 Embolotherapy Market for Neurological Diseases, by Type
6.4 By End User
6.5 By Country
6.5.1 U.S. Market Size and Forecast
6.5.1.1 By product
6.5.1.1.1 Embolic agents market, by type
6.5.1.1.2 Embolotherapy support devices market, by type
6.5.1.2 By procedure
6.5.1.2.1 TAE Market, By Product
6.5.1.2.1.1 TAE Embolic Agents Market, by Type
6.5.1.2.1.2 TAE Support Devices Market, by Type
6.5.1.2.2 TACE Market, By Product
6.5.1.2.2.1 TACE Embolic Agents Market, by Type
6.5.1.2.2.2 TACE Support Devices Market, by Type
6.5.1.2.3 TARE Market, By Product
6.5.1.2.3.1 TARE Embolic Agents Market, by Type
6.5.1.2.3.2 TARE Support Devices Market, by Type
6.5.1.3 By indication
6.5.1.3.1 Embolotherapy market for cancer, by type
6.5.1.3.2 Liver Cancer Embolotherapy Market, By Product
6.5.1.3.2.1 Liver Cancer Embolic Agents Market, by Type
6.5.1.3.3 Kidney Cancer Embolotherapy Market, By Product
6.5.1.3.3.1 Kidney Cancer Embolic Agents Market, by Type
6.5.1.3.4 Other Cancer Embolotherapy Market, By Product
6.5.1.3.4.1 Other Cancer Embolic Agents Market, by Type
6.5.1.3.5 Embolotherapy market for neurological diseases, by type
6.5.1.4 By end user
6.5.2 Canada Market Size and Forecast
6.5.2.1 By product
6.5.2.1.1 Embolic agents’ market, by type
6.5.2.1.2 Embolotherapy support devices market, by type
6.5.2.2 By procedure
6.5.2.2.1 TAE Market, By Product
6.5.2.2.1.1 TAE Embolic Agents Market, by Type
6.5.2.2.1.2 TAE Support Devices Market, by Type
6.5.2.2.2 TACE Market, By Product
6.5.2.2.2.1 TACE Embolic Agents Market, by Type
6.5.2.2.2.2 TACE Support Devices Market, by Type
6.5.2.2.3 TARE Market, By Product
6.5.2.2.3.1 TARE Embolic Agents Market, by Type
6.5.2.2.3.2 TARE Support Devices Market, by Type
6.5.2.3 By indication
6.5.2.3.1 Embolotherapy market for cancer, by type
6.5.2.3.2 Liver Cancer Embolotherapy Market, By Product
6.5.2.3.2.1 Liver Cancer Embolic Agents Market, by Type
6.5.2.3.3 Kidney Cancer Embolotherapy Market, By Product
6.5.2.3.3.1 Kidney Cancer Embolic Agents Market, by Type
6.5.2.3.4 Other Cancer Embolotherapy Market, By Product
6.5.2.3.4.1 Other Cancer Embolic Agents Market, by Type
6.5.2.3.5 Embolotherapy market for neurological diseases, by type
6.5.2.4 By end user
Chapter 7. Europe Market Size and Forecast
7.1 By Product
7.1.1 Embolic Agents Market, by Type
7.1.2 Embolotherapy Support Devices Market, by Type
7.2 By Procedure
7.2.1 TAE Market, By Product
7.2.1.1 TAE Embolic Agents Market, by Type
7.2.1.2 TAE Support Devices Market, by Type
7.2.2 TACE Market, By Product
7.2.2.1 TACE Embolic Agents Market, by Type
7.2.2.2 TACE Support Devices Market, by Type
7.2.3 TARE Market, By Product
7.2.3.1 TARE Embolic Agents Market, by Type
7.2.3.2 TARE Support Devices Market, by Type
7.3 By Indication
7.3.1 Embolotherapy Market for Cancer, by Type
7.3.1.1 Liver Cancer Embolotherapy Market, By Product
7.3.1.1.1 Liver Cancer Embolic Agents Market, by Type
7.3.1.2 Kidney Cancer Embolotherapy Market, By Product
7.3.1.2.1 Kidney Cancer Embolic Agents Market, by Type
7.3.1.3 Other Cancer Embolotherapy Market, By Product
7.3.1.3.1 Other Cancer Embolic Agents Market, by Type
7.3.2 Embolotherapy Market for Neurological Diseases, by Type
7.4 By End User
7.5 By Country
7.5.1 Germany Market Size and Forecast
7.5.1.1 By product
7.5.1.1.1 Embolic agents market, by type
7.5.1.1.2 Embolotherapy support devices market, by type
7.5.1.2 By procedure
7.5.1.2.1 TAE Market, By Product
7.5.1.2.1.1 TAE Embolic Agents Market, by Type
7.5.1.2.1.2 TAE Support Devices Market, by Type
7.5.1.2.2 TACE Market, By Product
7.5.1.2.2.1 TACE Embolic Agents Market, by Type
7.5.1.2.2.2 TACE Support Devices Market, by Type
7.5.1.2.3 TARE Market, By Product
7.5.1.2.3.1 TARE Embolic Agents Market, by Type
7.5.1.2.3.2 TARE Support Devices Market, by Type
7.5.1.3 By indication
7.5.1.3.1 Embolotherapy market for cancer, by type
7.5.1.3.2 Liver Cancer Embolotherapy Market, By Product
7.5.1.3.2.1 Liver Cancer Embolic Agents Market, by Type
7.5.1.3.3 Kidney Cancer Embolotherapy Market, By Product
7.5.1.3.3.1 Kidney Cancer Embolic Agents Market, by Type
7.5.1.3.4 Other Cancer Embolotherapy Market, By Product
7.5.1.3.4.1 Other Cancer Embolic Agents Market, by Type
7.5.1.3.5 Embolotherapy market for neurological diseases, by type
7.5.1.4 By end user
7.5.2 France Market Size and Forecast
7.5.2.1 By product
7.5.2.1.1 Embolic agents market, by type
7.5.2.1.2 Embolotherapy support devices market, by type
7.5.2.2 By procedure
7.5.2.2.1 TAE Market, By Product
7.5.2.2.1.1 TAE Embolic Agents Market, by Type
7.5.2.2.1.2 TAE Support Devices Market, by Type
7.5.2.2.2 TACE Market, By Product
7.5.2.2.2.1 TACE Embolic Agents Market, by Type
7.5.2.2.2.2 TACE Support Devices Market, by Type
7.5.2.2.3 TARE Market, By Product
7.5.2.2.3.1 TARE Embolic Agents Market, by Type
7.5.2.2.3.2 TARE Support Devices Market, by Type
7.5.2.3 By indication
7.5.2.3.1 Embolotherapy market for cancer, by type
7.5.2.3.2 Liver Cancer Embolotherapy Market, By Product
7.5.2.3.2.1 Liver Cancer Embolic Agents Market, by Type
7.5.2.3.3 Kidney Cancer Embolotherapy Market, By Product
7.5.2.3.3.1 Kidney Cancer Embolic Agents Market, by Type
7.5.2.3.4 Other Cancer Embolotherapy Market, By Product
7.5.2.3.4.1 Other Cancer Embolic Agents Market, by Type
7.5.2.3.5 Embolotherapy market for neurological diseases, by type
7.5.2.4 By end user
7.5.3 U.K. Market Size and Forecast
7.5.3.1 By product
7.5.3.1.1 Embolic agents market, by type
7.5.3.1.2 Embolotherapy support devices market, by type
7.5.3.2 By procedure
7.5.3.2.1 TAE Market, By Product
7.5.3.2.1.1 TAE Embolic Agents Market, by Type
7.5.3.2.1.2 TAE Support Devices Market, by Type
7.5.3.2.2 TACE Market, By Product
7.5.3.2.2.1 TACE Embolic Agents Market, by Type
7.5.3.2.2.2 TACE Support Devices Market, by Type
7.5.3.2.3 TARE Market, By Product
7.5.3.2.3.1 TARE Embolic Agents Market, by Type
7.5.3.2.3.2 TARE Support Devices Market, by Type
7.5.3.3 By indication
7.5.3.3.1 Embolotherapy market for cancer, by type
7.5.3.3.2 Liver Cancer Embolotherapy Market, By Product
7.5.3.3.2.1 Liver Cancer Embolic Agents Market, by Type
7.5.3.3.3 Kidney Cancer Embolotherapy Market, By Product
7.5.3.3.3.1 Kidney Cancer Embolic Agents Market, by Type
7.5.3.3.4 Other Cancer Embolotherapy Market, By Product
7.5.3.3.4.1 Other Cancer Embolic Agents Market, by Type
7.5.3.3.5 Embolotherapy market for neurological diseases, by type
7.5.3.4 By end user
7.5.4 Italy Market Size and Forecast
7.5.4.1 By product
7.5.4.1.1 Embolic agents market, by type
7.5.4.1.2 Embolotherapy support devices market, by type
7.5.4.2 By procedure
7.5.4.2.1 TAE Market, By Product
7.5.4.2.1.1 TAE Embolic Agents Market, by Type
7.5.4.2.1.2 TAE Support Devices Market, by Type
7.5.4.2.2 TACE Market, By Product
7.5.4.2.2.1 TACE Embolic Agents Market, by Type
7.5.4.2.2.2 TACE Support Devices Market, by Type
7.5.4.2.3 TARE Market, By Product
7.5.4.2.3.1 TARE Embolic Agents Market, by Type
7.5.4.2.3.2 TARE Support Devices Market, by Type
7.5.4.3 By indication
7.5.4.3.1 Embolotherapy market for cancer, by type
7.5.4.3.2 Liver Cancer Embolotherapy Market, By Product
7.5.4.3.2.1 Liver Cancer Embolic Agents Market, by Type
7.5.4.3.3 Kidney Cancer Embolotherapy Market, By Product
7.5.4.3.3.1 Kidney Cancer Embolic Agents M
Want a report tailored exactly to your business need?
Request CustomizationEmpowering Leaders Across the Globe
Leading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.



Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights

We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives

Request the Free Sample Pages
